PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Ann: Primary and Secondary endpoints met in MPS I Trial, page-8

  1. 733 Posts.
    lightbulb Created with Sketch. 165
    The seller that has been around now for a few weeks - UBS continues to use every volume opportunity to keep selling stock. I will bet they are the seller killing the rally again.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.